PDF(719 KB)
PDF(719 KB)
PDF(719 KB)
芜湖市2021—2023年预防乙肝母婴传播工作效果分析
Analysis on the effectiveness of preventing mother-to-child transmission of hepatitis B in Wuhu City from 2021 to 2023
目的 评估芜湖市预防乙肝母婴传播工作的实施效果。方法 研究纳入2021—2023年在芜湖市分娩的所有产妇、HBsAg阳性的产妇及其所生儿童,分析产妇乙肝HBV-DNA病毒载量(简称HBV-DNA)检测和治疗情况,以及其所生儿童干预和母婴阻断结局情况。结果 芜湖市2021—2023年助产机构产妇共有57 474名,全部在孕期接受过乙肝检测,乙肝检测率为100.00%,检出HBsAg阳性产妇2 054例,阳性检出率为3.57%。2 054例HBsAg阳性产妇中,1 328例在孕期接受过HBV-DNA检测,检测率为64.65%;89例在孕期接受抗病毒治疗,治疗率为56.33%。乙肝暴露儿童共2 074例,均注射了首剂乙肝疫苗和免疫球蛋白,其中接受HBsAg检测1 376例,HBsAg阳性8例,乙肝母婴传播率为0.58%(8/1 376)。结论 芜湖市预防乙肝母婴传播的效果较好,但乙肝暴露儿童随访工作尚需进一步加强。
Objective To evaluate the effectiveness of the work on preventing mother-to-child transmission of hepatitis B in Wuhu City.Methods This study included all pregnant women,HBsAg positive mothers and their children who gave birth in Wuhu City from 2021 to 2023,and analyzed the detection and treatment of HBV-DNA viral load (HBV-DNA) in pregnant women,as well as the outcomes of intervention and mother-to-child blocking in their children.Results There were a total of 57 474 pregnant women in midwifery institutions in Wuhu City from 2021 to 2023,all of them had been received hepatitis B testing during pregnancy,and the hepatitis B testing rate was 100.00%.2 054 pregnant women were detected as HBsAg positive,with a positive detection rate of 3.57%.Among the 2 054 HBsAg positive cases,1 328 had received HBV-DNA testing during pregnancy,with a detection rate of 64.65%,and 89 cases received antiviral treatment during pregnancy,with a treatment rate of 56.33%.A total of 2 074 hepatitis B-exposed children all received the first dose of the hepatitis B vaccine and immunoglobulin,among whom 1 376 underwent HBsAg testing. Of these,8 tested positive for HBsAg,resulting in a hepatitis B mother-to-child transmission rate of 0.58%(8/1 376).Conclusion The effectiveness of preventing mother-to-child transmission of Hepatitis B in Wuhu City is good,but the follow-up work for children exposed to hepatitis B needs to be further strengthened.
乙型肝炎 / 抗病毒治疗 / 乙肝暴露儿童 / 免疫后血清学检测 / 乙肝母婴传播
Hepatitis B / Antiviral therapy / Children exposed to hepatitis B / Serological testing after immunization / Mother-to-child transmission of hepatitis B
| [1] |
|
| [2] |
Polaris Observatory Collaborators. Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):383-403.
|
| [3] |
Treating high-risk women with antivirals in their third trimester is a promising intervention to further reduce perinatal transmission in neonates born to hepatitis B surface antigen positive [HBsAg(+)] mothers.We estimated the number of perinatal infections based on coverage and effectiveness of hepatitis B immunization. We compared cost-effectiveness of different approaches to identify high-risk women for antiviral treatment, by region and urban/rural residence.Of the 16.59 million live births in 2015, 1.04 million infants (6.3%) were born to HBsAg(+) mothers and 268 201 infants (1.6%) to HBsAg(+) and HBeAg(+) dual-positive mothers. Despite immunoprophylaxis, 51 478 perinatal hepatitis B virus (HBV) transmissions were estimated to have occurred from HBsAg and HBeAg dual-positive mothers in 2015. Using HBeAg or HBV viral load testing to identify high-risk pregnant women and to treat them with Tenofovir, the incremental cost ranged from US$68.2 million to US$90.3 million. Assuming HBV viral load testing is available and used to guide treatment and all women with HBV viral loads >200 000 IU/ml are treated, 25 912 infections would be averted at a projected cost of US$3500 per infection averted.Identifying high-risk pregnant women and providing them with antiviral treatment is feasible and cost-effective to interrupt perinatal HBV transmissions. Policy options should be urgently explored in order for China to reach the HBV elimination goal of 0.1% prevalence among children by 2030.
|
| [4] |
China has the highest number of hepatitis B and C cases globally. Despite remarkable achievements, China faces daunting challenges in achieving international targets for hepatitis elimination. As part of a large-scale project assessing China’s progress in achieving health-related Sustainable Development Goals using quantitative, qualitative data and mathematical modelling, this paper summarises the achievements, gaps and challenges, and proposes options for actions for hepatitis B and C control. China has made substantial progress in controlling chronic viral hepatitis. The four most successful strategies have been: (1) hepatitis B virus childhood immunisation; (2) prevention of mother-to-child transmission; (3) full coverage of nucleic acid amplification testing in blood stations and (4) effective financing strategies to support treatment. However, the total number of deaths due to hepatitis B and C is estimated to increase from 434 724 in 2017 to 527 829 in 2030 if there is no implementation of tailored interventions. Many health system barriers, including a fragmented governance system, insufficient funding, inadequate service coverage, unstandardised treatment and flawed information systems, have compromised the effective control of hepatitis B and C in China. We suggest five strategic priority actions to help eliminate hepatitis B and C in China: (1) restructure the viral hepatitis control governance system; (2) optimise health resource allocation and improve funding efficiency; (3) improve access to and the quality of the health benefits package, especially for high-risk groups; (4) strengthen information systems to obtain high-quality hepatitis epidemiological data; (5) increase investment in viral hepatitis research and development.
|
| [5] |
国家卫生健康委办公厅. 国家卫生健康委关于印发消除艾滋病、梅毒和乙肝母婴传播行动计划(2022—2025年)的通知[EB/OL].(2022-12-05)[2024-03-19]. http://www.nhc.gov.cn/fys/s3581/202212/afe6bc9626be45a0b25bee93f01fef10.shtml.
|
| [6] |
WHO. Global progress report on HIV,viral hepatitis and sexually transmitted infections,2021.Accountability for the global health sector strategies 2016-2021: actions for impact[EB/OL].(2021-07-15)[2024-03-19]. https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf.
|
| [7] |
中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会. 阻断乙型肝炎病毒母婴传播临床管理流程(2021年)[J]. 临床肝胆病杂志, 2021, 37(3):527-531.
|
| [8] |
罗雅丽, 唐伟平, 朱娜玲, 等. 2018—2020年广东省深圳市宝安区预防乙肝母婴传播状况及效果分析[J]. 中国妇幼卫生杂志, 2021, 12(6):14-17.
|
| [9] |
苏晓洁, 余擎. 2011—2021年我国乙型病毒性肝炎流行病学特征及时空聚集性分析[J]. 现代预防医学, 2024, 51(8):1384-1389.
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
周乙华, 杨慧霞, 胡娅莉, 等. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 临床肝胆病杂志, 2020, 36(7):1474-1481.
|
| [14] |
曾妮, 叶兴, 黄河浪. 乙肝免疫球蛋白联合乙肝疫苗阻断乙型肝炎母婴传播的系统评价[J]. 中华疾病控制杂志, 2017, 21(1):48-51+60.
|
| [15] |
徐靓亮, 郑徽, 王富珍, 等. 乙型肝炎表面抗原阳性母亲所生儿童免疫后血清学检测实施进展[J]. 中国疫苗和免疫, 2019, 25(5):605-610.
|
| [16] |
吴炜林, 王睿, 王润, 等. 芜湖市乙肝免疫球蛋白与乙肝疫苗联合免疫阻断乙肝病毒母婴传播效果评价[J]. 安徽预防医学杂志, 2021, 27(5):374-376+398.
|
| [17] |
贺玉芬, 梁培芳. 新生儿接种乙肝疫苗低、无应答调查及再免疫效果分析[J]. 实用预防医学, 2015, 22(9):1079-1081.
|
| [18] |
国家卫生健康委办公厅. 国家卫生健康委办公厅关于印发艾滋病、梅毒和乙肝母婴传播工作规范(2020 年版)的通知[EB/OL].(2020-11-12)[2024-03-19]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml.
|
| [19] |
谭楚生, 陈福辉, 赵玉芹, 等. 南昌市2016—2019年HBsAg阳性母亲所生婴儿乙肝疫苗接种与母婴阻断效果分析[J]. 安徽预防医学杂志, 2021, 27(6):466-469.
|
利益冲突声明 所有作者声明无利益冲突
/
| 〈 |
|
〉 |
